Biogen Stock's Tecfidera Embarrasses Wall Street

Sales of Biogen's (BIIB) MS drug Tecfidera soared again last quarter as it won market share away from competing oral MS drugs from Novartis (NVS) and Sanofi (SNY).

Jul 23, 2014 at 4:31PM


Source: Biogen Idec

It's hard to imagine that Biogen Idec (NASDAQ:BIIB) believed Tecfidera would become one of the top selling multiple sclerosis drugs just one year after its launch, but that's exactly what happened.

Tecfidera was the third oral MS drug to get the FDA green-light when it was approved in March 2013, but while Novartis (NYSE:NVS), which markets Gilenya, and Sanofi (NYSE:SNY), which markets Aubagio, won approval first, both companies first mover advantage is disappearing quickly.

BIIB Chart

BIIB data by YCharts

Another great quarter
Biogen's second quarter sales jumped 40% year-over-year to $2.4 billion thanks to Tecfidera's sales surging from $192 million to $700 million, including $115 million in sales outside America.

As a result, Biogen is bumping up its full year sales growth forecast to between 38% to 41% and guiding for non-GAAP earnings per share of between $12.90 and $13.10. Exiting 2013, the company was estimating its full year sales would grow between 22% and 25%, producing non-GAAP EPS of between $11 and $11.20.

That earnings confidence stems from delivering EPS of $3.01 in the second quarter and $5.03 in the first six months, up from $2.06 and $3.85 last year, respectively.


Source: Biogen Idec

An even brighter future
More than half of the globe's multiple sclerosis patients live in Europe, and Tecfidera is only now launching in those markets.

Since Tecfidera has already displaced Novartis' Gilenya as the top selling oral MS drug in America, its likely not a stretch to assume a similar market share grab is coming in Europe as Biogen inks new pricing agreements with additional countries.

If that proves true, Tecfidera could have plenty of revenue running room over the coming year. Gilenya's sales improved 28% to $606 million in the second quarter, but that growth was driven by a 48% jump in overseas markets where it doesn't compete broadly with Tecfidera (yet).

Tecfidera could also find that it nabs business away from Sanofi's Aubagio too. Aubagio's revenue jumped by 305% year-over-year to $78 million in the first quarter after Sanofi agreed to price concessions.

Other reasons for optimism
Tecfidera is already a blockbuster and it will offer Biogen sales growth tailwinds at least through next year, but Biogen could see sales climb thanks to other new drugs too.

In March, the FDA approved Biogen's hemophilia B drug Alprolix and Biogen began marketing the drug in May. Alprolix sales totaled just $10 million in its first month or so on the market, but sales may continue to climb given Alprolix's once-weekly dosing.

The company's Plegridy, a subcutaneous pegylated interferon beta 1 drug for relapsing MS, got a positive opinion from a key European advisory committee in May that should clear the way to eventual EU approval, further strengthening the company's MS franchise.

And In June, the FDA gave Biogen's hemophilia A drug, Eloctate, a green light too. Eloctate offers a more convenient dosing schedule of once every three to five days version the current treatment regimen of three times a week or every other day. That means that Eloctate could reduce the number of patient's infusions by more than 50 a year.

Fool-worthy final thoughts
Tecfidera gives Biogen its first blockbuster MS drug since Tysabri and while the drug is already selling at annualized $2.8 billion clip, sales should march much higher as it gains stronger market share in Europe.

While Tecfidera's impact is far larger than Alprolix and Eloctate, those two hemophilia drugs help diversify Biogen's revenue away from MS. Both drugs could eventually generate hundreds of millions in annualized sales given the significant need for new treatment among the more than 142,000 people living with hemophilia A and 28,000 people living with hemophilia B worldwide.

Leaked: This coming blockbuster will make even Biogen jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

Todd Campbell has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.


Compare Brokers